ProCE Banner Activity

Phase III MAIA: Daratumumab + Len/Dex vs Len/Dex in Transplantation-Ineligible Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
In this interim analysis, addition of daratumumab to lenalidomide/dexamethasone reduced risk of progression or death by 44% and improved the rate of MRD negativity.

Released: December 10, 2018

Expiration: December 09, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology